A Post-Marketing, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Omaveloxolone During Pregnancy and/or Lactation
Latest Information Update: 21 Oct 2024
Price :
$35 *
At a glance
- Drugs Omaveloxolone (Primary)
- Indications Friedreich's ataxia
- Focus Adverse reactions
- Sponsors Reata Pharmaceuticals
- 18 Oct 2024 Status changed from not yet recruiting to recruiting.
- 14 Oct 2024 New trial record